Literature DB >> 23849057

Biochemistry of cardiomyopathy in the mitochondrial disease Friedreich's ataxia.

Darius J R Lane1, Michael Li-Hsuan Huang, Samantha Ting, Sutharshani Sivagurunathan, Des R Richardson.   

Abstract

FRDA (Friedreich's ataxia) is a debilitating mitochondrial disorder leading to neural and cardiac degeneration, which is caused by a mutation in the frataxin gene that leads to decreased frataxin expression. The most common cause of death in FRDA patients is heart failure, although it is not known how the deficiency in frataxin potentiates the observed cardiomyopathy. The major proposed biochemical mechanisms for disease pathogenesis and the origins of heart failure in FRDA involve metabolic perturbations caused by decreased frataxin expression. Additionally, recent data suggest that low frataxin expression in heart muscle of conditional frataxin knockout mice activates an integrated stress response that contributes to and/or exacerbates cardiac hypertrophy and the loss of cardiomyocytes. The elucidation of these potential mechanisms will lead to a more comprehensive understanding of the pathogenesis of FRDA, and will contribute to the development of better treatments and therapeutics.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23849057     DOI: 10.1042/BJ20130079

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  7 in total

1.  Stable isotopes and LC-MS for monitoring metabolic disturbances in Friedreich's ataxia platelets.

Authors:  Andrew J Worth; Sankha S Basu; Eric C Deutsch; Wei-Ting Hwang; Nathaniel W Snyder; David R Lynch; Ian A Blair
Journal:  Bioanalysis       Date:  2015       Impact factor: 2.681

Review 2.  Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases.

Authors:  Annita Kolnagou; Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2014-12-26

Review 3.  Fixing frataxin: 'ironing out' the metabolic defect in Friedreich's ataxia.

Authors:  A Anzovino; D J R Lane; M L-H Huang; D R Richardson
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

4.  The pathogenesis of cardiomyopathy in Friedreich ataxia.

Authors:  Arnulf H Koeppen; R Liane Ramirez; Alyssa B Becker; Sarah T Bjork; Sonia Levi; Paolo Santambrogio; Patrick J Parsons; Pamela C Kruger; Karl X Yang; Paul J Feustel; Joseph E Mazurkiewicz
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

Review 5.  Neuro-Cardio Mechanisms in Huntington's Disease and Other Neurodegenerative Disorders.

Authors:  Bethan J Critchley; Mark Isalan; Michal Mielcarek
Journal:  Front Physiol       Date:  2018-05-23       Impact factor: 4.566

6.  Hyperactivation of mTOR and AKT in a cardiac hypertrophy animal model of Friedreich ataxia.

Authors:  Wing-Hang Tong; Hayden Ollivierre; Audrey Noguchi; Manik C Ghosh; Danielle A Springer; Tracey A Rouault
Journal:  Heliyon       Date:  2022-08-23

7.  E3 Ligase RNF126 Directly Ubiquitinates Frataxin, Promoting Its Degradation: Identification of a Potential Therapeutic Target for Friedreich Ataxia.

Authors:  Monica Benini; Silvia Fortuni; Ivano Condò; Giulia Alfedi; Florence Malisan; Nicola Toschi; Dario Serio; Damiano Sergio Massaro; Gaetano Arcuri; Roberto Testi; Alessandra Rufini
Journal:  Cell Rep       Date:  2017-02-21       Impact factor: 9.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.